



Check-Cap Announces Extraordinary General Meeting of Shareholders

ISFIYA, Israel, May 7, 2015 /PRNewswire/ -- Check-Cap Ltd. (Nasdaq: CHEK, CHEKW) ("Check-Cap" or the "Company"), a clinical stage medical diagnostics company engaged in the development of a preparation-free ingestible imaging capsule screening for colorectal cancer, announced today that it will hold an Extraordinary General Meeting of Shareholders (the "Meeting") on Tuesday, May 19, 2015. Shareholders of record at the close of business on April 9, 2015, are entitled to notice of and to vote at the Meeting.

At the Meeting, the following proposals will be presented for shareholder approval:

- To ratify the election of, or elect, each of the following as external directors, within the meaning of the Israel Companies Law, 5759-1999: (i) Mr. Yuval Yanai; and (ii) Ms. Mary Jo Gorman, each for an initial three-year term;
- Subject to the approval of proposal 1, to ratify and approve the compensation to be paid to each of the external directors, consisting of an annual fee and a one-time option grant; and
- To approve the terms of engagement of Mr. William Densel, as President of U.S. Operations.

Additional Details

The Meeting will be held at 4:00 p.m. (Israel time) at the Company's offices at the Check-Cap Building, Abba Hushi Avenue, P.O. Box 1271, Isfiya, 30090, Mount Carmel, Israel.

Shareholders may access and review the Proxy Statement as well as the accompanying Proxy Card via the website of the U.S. Securities and Exchange Commission at www.sec.gov as well as in the Investors section of the Check-Cap website at <http://ir.check-cap.com/>, and also at the Check-Cap offices during regular business hours (Check-Cap Building, Abba Hushi Avenue, P.O. Box 1271, Isfiya, 30090, Mount Carmel, Israel; Tel: +972-4-830-3400). The Company's representative is Mr. Lior Torem, Chief Financial Officer (Tel: +972-4-830-3415). Detailed voting instructions are provided both in the Proxy Statement and the Proxy Card.

About Check-Cap

Check-Cap is a clinical stage medical diagnostics company focused on the development of gastrointestinal imaging devices. The Company's lead product is an endoscopy capsule with a colon imaging system for colorectal cancer and clinically-significant pre-cancerous polyps that utilizes proprietary, ultra-low-energy X-ray-based measurement technology to safely generate high-resolution, 3-dimensional imagery of the colon without cleansing or other aggressive bowel preparation. This solution is designed to increase compliance with screening recommendations. The Check-Cap imaging system is not cleared for marketing in any jurisdiction.

Legal Notice Regarding Forward-Looking Statements

This press release contains "forward-looking statements." Words such as "may," "should," "could," "would," "predicts," "potential," "continue," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," and similar expressions, as well as statements in future tense, often signify forward-looking statements. Forward looking statements should not be read as a guarantee of future performance or results and may not be accurate indications of when such performance or results will be achieved. Forward-looking statements are based on information that the Company has when those statements are made or management's good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. For a discussion of these and other risks that could cause such differences and that may affect the realization of forward looking statements, please refer to the "Special Note On Forward-looking Statements" and "Risk Factors" in the Company's Registration Statement on Form F-1 and other filings with the Securities and Exchange Commission (SEC). Investors and security holders are urged to read these documents free of charge on the SEC's web site at <http://www.sec.gov>. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

CONTACT:

Investors (Israel)
Hadas Friedman-Zick
KM Investor Relations
hadas@km-ir.co.il

Investors (U.S.)
David Carey
Lazar Partners Ltd.
212-867-1768
dcarey@lazarpartners.com

SOURCE Check-Cap Ltd.

<https://ir.check-cap.com/2015-05-07-Check-Cap-Announces-Extraordinary-General-Meeting-of-Shareholders>